Equity Research · Tuesday, September 1, 2026
PFE Stock Analysis for September 2026
Pfizer Inc.
Price at Analysis
1Y Price Target
$30.00
+5.4%
vs current price
Technical Setup
RSI 63 / bullish MACD
Support context: $23.58. Resistance context: $28.75.
Valuation Snapshot
P/E ~9.5x forward (EPS guidance $2.80-$3.00) / P/S ~0.26x (FY26 revenue guidance $61.5B)
Market cap $159.36B; revenue ~$61.5B FY2026 guidance; Q2 2026 $15.0B (+3% YoY).
Risk Watch
2027-2028 patent cliff
Eliquis, Ibrance, and other blockbusters lose exclusivity, threatening a double-digit percentage of the ~$61.5B revenue base just as Covid products normalize at $4B.
01 · Summary
Executive Summary
Pfizer at $28.46 sits within 1% of its 52-week high, meaning the market has already re-rated the stock off its lows on the back of Q2 2026 beats, raised revenue guidance ($61.5B midpoint), and $2.5B in incremental cost cuts. The valuation is optically cheap (~9-10x forward EPS of $2.80-$3.00) with a 6.6% dividend yield, but that yield is the market's way of pricing real risk: a 2027-2028 patent cliff (Eliquis, Ibrance, Xeljanz era products), GAAP earnings down 58% this year, two discontinued obesity candidates, a CFO departure, and Covid franchise erosion (Covid product guidance cut from ~$5B to $4B). The stock is no longer 'hated and cheap' — it has rallied ~21% off the lows and now trades at the top of its range with fundamentals that are merely stable, not accelerating. Non-COVID growth of 5% operational is real but modest, and the guidance raise leans heavily on Eliquis, which faces its own patent clock. On a 1Y view, the risk/reward is balanced: dividend support and cost cuts cushion downside, but the patent cliff looms and the easy re-rating has happened. On a 3Y view, Pfizer must prove the Seagen/Metsera-driven oncology and obesity pipeline can outrun the cliff — plausible but unproven. Verdict: neutral, with targets of ~$30 in 1Y and ~$33 in 3Y, roughly a total-return story driven by the dividend rather than capital appreciation.
02 · Scenario Modeling
Price Targets
$30.00+5.4%
$33.00+15.9%
1-Year scenario price targets · Dashed line = current price
02 · Scenario Modeling
Scenario Analysis
| Scenario | 1Y Target | 1Y Growth | 3Y Target | 3Y Growth |
|---|---|---|---|---|
↑↑Hyper Bull | $40.00 | +40.5% | $55.00 | +93.3% |
↑Bull | $33.00 | +16.0% | $38.00 | +33.5% |
→Neutral | $30.00 | +5.4% | $33.00 | +16.0% |
↓Bear | $24.00 | -15.7% | $20.00 | -29.7% |
↓↓Hyper Bear | $19.00 | -33.2% | $15.00 | -47.3% |
03 · Fundamentals
Key Financial Metrics
- Earnings Per Share (EPS)
- $2.80-$3.00 FY2026 adjusted guidance
- Revenue
- ~$61.5B FY2026 guidance; Q2 2026 $15.0B (+3% YoY)
- P/E Ratio
- ~9.5x forward (EPS guidance $2.80-$3.00)
- P/S Ratio
- ~0.26x (FY26 revenue guidance $61.5B)
- Market Cap
- $159.36B
- Net Income
- GAAP earnings down 58% YTD; adjusted EPS $0.77 in Q2
- Dividend Yield
- ~6.6%
- Short Interest
- N/A (no elevated short interest data; bearish sentiment is narrative-driven, not position-driven)
- 52-Week Low
- $23.58
- 52-Week High
- $28.75
02 · Scenario Modeling
Technical Overview
Quant overlays derived from the existing 1Y OHLCV series: trend stack, sigma bands, regression fit, drawdown regime, and a composite signal model.
RSI (14)
63.4
Momentum Stack
1M +12.2% / 3M +6.8%
Volatility Regime
22.1% 20D vol
Regression Fit
+5.5% vs trend
Drawdown Curve
Distance from rolling peak, useful for regime stress and recovery speed.
-2.1%
Trend Regime
neutral
Mixed stack
Composite Signal
neutral
Neutral (+2)
Mean Reversion
neutral
+0.88 sigma
Breakout Status
neutral
Inside channel
Range Percentile
bullish
85th pct
Volume Impulse
bearish
0.71x 20D avg
Quant Dashboard
A compact read on trend persistence, stretch, realized risk, and breakout behavior.
- 1M Return
- +12.2%
- 6M Return
- +1.1%
- 1Y Return
- N/A
- ATR (14)
- $0.58
- 20D Vol
- 22.1%
- 60D Vol
- 22.5%
- Regression R²
- 0.12
- Price Z-Score
- +0.88
- 52W High
- $28.75
- 52W Low
- $23.58
- Range Position
- 85th pct
- Latest Volume
- 27.2M
04 · Research
Micro Analysis
Q2 2026 showed $15.0B revenue (+3% YoY, +1% operational), adjusted EPS of $0.77 (vs $0.78 prior year), raised FY revenue guidance to $60.5-62.5B, and maintained EPS guidance of $2.80-$3.00. Non-COVID revenue grew 5% operationally, led by Padcev (+23%), the tafamidis franchise ($1.76B, +10% QoQ), and Abrysvo (+45.5%). However, Covid product guidance was cut to $4B from ~$5B, two obesity candidates were discontinued, and GAAP earnings fell 58% this year — fueling dividend-cut speculation. The $43B Seagen acquisition is starting to contribute, and Metsera offers obesity optionality, but the pipeline must offset the 2027-2028 patent cliff.
Q2 beat with raised guidance, but low-quality mix
Revenue of $15.0B beat estimates and guidance midpoint rose $500M to $61.5B, but the raise relies on Eliquis (running out patent clock) while Covid products were cut to $4B from ~$5B — a $1B headwind absorbed by non-COVID outperformance of $1.5B.
GAAP earnings down 58% — dividend sustainability question
Adjusted EPS guidance of $2.80-$3.00 supports the ~$1.88 dividend (~6.6% yield) on a cash basis, but the 58% GAAP earnings decline and $6-7B remaining deployment capacity signal thinner coverage than the headline yield suggests. A cut is not imminent but the market correctly prices elevated risk.
Oncology rebuild via Seagen showing traction
Padcev +23%, ADC portfolio expanding, eight+ targeted blockbusters by 2030. Seagen integration is the core of the post-Covid pivot and is delivering, though Ibrance ($2.07B, ~6% growth) shows legacy oncology is mature.
Obesity setbacks and execution churn
Discontinuation of MET-224o and PF-07976016 removes internal obesity shots; the bet now rests on the Metsera acquisition. Combined with a CFO departure (Denton out, interim CFO Guegan), management execution risk is elevated at a critical juncture.
Cost cuts provide EPS bridge
$2.5B in additional savings from two programs starting 2027 through 2029, layered on existing programs, underpin the $2.80-$3.00 EPS guide and partially offset the coming patent cliff.
04 · Research
Macro Analysis
The macro setup is mixed. A new Fed regime under Kevin Warsh with potential rate shifts favors high-yield defensive names like PFE (6.6% yield) if rates fall, but 'regime change' rhetoric also implies policy uncertainty. Sector-wide, drug pricing scrutiny (IRA negotiation — Eliquis is already negotiated), RFK-era vaccine policy volatility hitting Comirnaty/Abrysvo demand, and a wave of 2027-2028 patent expirations across big pharma create structural headwinds. AI-driven discovery and the ADC/obesity arms race favor companies with capital and pipelines — Pfizer has both but has been a fast follower, not a leader.
Fed regime change favors yield plays
With Kevin Warsh as Fed Chair and potential rate cuts, a 6.6% yielder trading at ~9x earnings becomes more attractive to income investors; lower discount rates support dividend-stock multiples.
Vaccine policy and IRA pricing pressure
Covid product guidance cut to $4B reflects softening vaccine demand amid shifting US vaccine policy; Eliquis faces IRA-negotiated pricing, compressing the cash engine just before its 2027-2028 patent expiry.
Patent cliff is sector-wide but PFE-heavy
2027-2028 expirations (Eliquis, Ibrance, Xeljanz, Vyndaqel later) could remove $15B+ of revenue by decade-end; management guides to recovery and high-single-digit growth by 2030, but that requires flawless pipeline execution.
Obesity/GLP-1 market arms race
The obesity market is the largest TAM in pharma; Pfizer's Metsera bet gives it a seat at the table against Lilly and Novo, but it is years behind and the internal candidates just failed.
05 · Growth
Untapped Revenue Opportunities
Seagen oncology franchise scaling
highPadcev +23% with expanded FDA label; ADC platform plus eight+ targeted blockbusters by 2030 could rebuild $15-20B of oncology revenue to offset the patent cliff.
Metsera obesity assets
highAcquired obesity pipeline (injectable/oral amylin candidates) addresses the largest growth market in pharma; even a niche share of a $100B+ market by 2030 is material.
Tafamidis franchise expansion
mediumVyndamax/Vyndaqel at $1.76B quarterly (+10% QoQ) with expanding transthyretin amyloidosis diagnosis rates and new indications.
Cost programs funding pipeline/BDS
medium$2.5B incremental savings (2027-2029) plus $6-7B deployable capital for bolt-ons in oncology, IMIDs, and obesity.
06 · Catalysts
Headwinds & Tailwinds
↓ Headwinds
2027-2028 patent cliff
highEliquis, Ibrance, and other blockbusters lose exclusivity, threatening a double-digit percentage of the ~$61.5B revenue base just as Covid products normalize at $4B.
Dividend sustainability concerns
highGAAP earnings down 58% this year; the 6.6% yield prices in cut risk. Any dividend action would likely pressure the stock 10-15% even if strategically rational.
Covid franchise decay
mediumCovid product guidance cut from ~$5B to $4B with Comirnaty demand eroding further amid vaccine policy shifts.
Obesity pipeline failures and management churn
mediumTwo internal obesity candidates discontinued; CFO departure adds execution uncertainty during the most important pipeline transition in a decade.
IRA pricing and policy risk
mediumEliquis already faces negotiated Medicare pricing; broader drug-pricing policy could compress margins across the portfolio.
↑ Tailwinds
Deep value with dividend support
high~9-10x forward EPS, P/S ~0.26x on $61.5B revenue, and a 6.6% yield create a valuation floor; Morningstar fair value is $32 with a narrow moat rating.
Non-COVID growth momentum
medium5% operational non-COVID growth with $1.5B outperformance vs guidance; newer launches (Padcev, Abrysvo, tafamidis) growing double digits.
Cost discipline
medium$2.5B new savings through 2029 plus existing programs protect the $2.80-$3.00 EPS range through the patent cliff.
Rate environment
mediumPotential Fed easing under Warsh supports high-yield defensive equities and could compress the equity risk premium on PFE.
07 · TL;DR
Analysis Summary
- Ticker
- PFE
- Company
- Pfizer Inc.
- Analysis Date
- 2026-09-01
- Price at Analysis
- $28.46
- Rating
- Hold
- 1Y Price Target
- $30.00
- 3Y Price Target
- $33.00
- Market Cap
- $159.36B
- P/E Ratio
- ~9.5x forward (EPS guidance $2.80-$3.00)
This analysis was generated on 2026-09-01 when PFE was trading at $28.46. The base-case 1-year price target is $30.00 (+5.4% implied return). Scenario range: $19.00 (hyper bear) to $40.00 (hyper bull).